A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 07 Jun 2016 Status changed from recruiting to active, no longer recruiting, according to results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 18 Mar 2013 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University, ECOG2408).
- 07 Dec 2012 New source identified and integrated (Mayo Clinic ; 10-007760)